# How should I treat a DES restenosis in a graft anastomosis with challenging access and multiple previous coronary interventions?



**Raúl S. Herrera-Nogueira**<sup>1</sup>, MD; Shweta Sahay<sup>1</sup>, MD; Pablo Salinas<sup>1</sup>, MD, PhD; Ivan J. Nuñez-Gil<sup>1</sup>, MD, PhD; Luis Nombela-Franco<sup>1\*</sup>, MD

1. Cardiovascular Institute, Hospital Universitario Clínico San Carlos, Madrid, Spain

Invited experts: Giulio G. Stefanini<sup>2</sup>, MD, PhD; Giuseppe Ferrante<sup>2</sup>, MD, PhD; Paolo Pagnotta<sup>2</sup>, MD; Bernhard Reimers<sup>2</sup>, MD;
Fernando Alfonso<sup>3</sup>, MD, PhD, FESC; Paula Antuña<sup>3</sup>, MD; Fernando Rivero<sup>3</sup>, MD
Cardiovascular Department, Humanitas Research Hospital, Rozzano, Milan, Italy; 3. Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain

The concluding section "How did I treat?" together with the complete references and the supplementary data are published online at: http://www.pcronline.com/eurointervention/97th\_issue/303

#### CASE SUMMARY

**BACKGROUND:** An 84-year-old male with previous history of multiple surgical and percutaneous coronary revascularisations presented with unstable angina.

**INVESTIGATION:** Coronary angiogram, ECG, echocardiogram.

**DIAGNOSIS:** Severe three-vessel disease with only one graft patent. This graft is a right internal mammary artery connected to a radial graft and to a marginal. In-stent restenosis in the radial graft anastomosis to the marginal. Left ventricle dysfunction.

**MANAGEMENT:** Coronary revascularisation with a triaxial "grandmother, mother and child" system.

**KEYWORDS:** coronary revascularisation, in-stent restenosis, mother and child

#### PRESENTATION OF THE CASE

An 84-year-old male with multivessel coronary artery disease and permanent atrial fibrillation (AF) on anticoagulation, also with hypertension, type 2 diabetes mellitus and dyslipidaemia, presented with unstable angina. He had an extensive history of coronary intervention including the following. 1) 1983 - coronary artery bypass graft (CABG) with saphenous vein graft (SVG) to the left anterior descending (LAD), the left circumflex (LCx) and the posterior descending arteries (PDA) for acute inferoposterior myocardial infarction (MI). 2) 1989 - repeat CABG for angina (previous grafts occluded) with left internal mammary artery (LIMA) to LAD, SVG to first obtuse marginal (OM1) and PDA. 3) 2002 - percutaneous coronary intervention (PCI) of saphenous graft to OM1 with two stents after presenting with unstable angina with diffuse native vessel disease and blocked grafts. 4) 2003 - CABG with right internal mammary artery (RIMA) extended with a radial graft to the OM1 for ongoing angina. 5) 2014 - admitted with angina (CCS grade III-IV). Angiography revealed severe stenosis of the RIMA radial graft to OM1 anastomosis. After a failed attempt at percutaneous transluminal coronary angioplasty (PTCA) via the right femoral route (144 cm standard PTCA balloons could not reach the target lesion with a 90 cm guiding catheter), a 2.5×18 mm Resolute stent (Medtronic, Minneapolis, MN, USA) was successfully implanted in the OM1, via the right brachial artery approach in a second attempt

\*Corresponding author: Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040 Madrid, Spain. E-mail: luisnombela@yahoo.com



two days later. A 7 Fr internal mammary (IM) catheter, shortened by approximately 30 cm, was placed at the ostium of the RIMA and through it a 6 Fr GuideLiner® V3 catheter (Vascular Solutions, Minneapolis, MN, USA) was advanced into the RIMA followed by successful delivery of a  $1.5 \times 15$  mm Sprinter® Legend balloon (Medtronic, Minneapolis, MN, USA) and a Resolute drug-eluting stent (Medtronic). 6) June 2015 – admitted with unstable angina. Angiogram showed in-stent restenosis (ISR) in the graft anastomosis to the OM1 which was successfully treated with simple balloon angioplasty after unsuccessfully attempting drug-eluting balloon (DEB) delivery (the same technical strategy of a shortened 7 Fr IM catheter plus a 6 Fr GuideLiner V3 was used).

His current admission in August 2015 was for resting chest pain of 10 days duration which persisted in spite of nitrate infusion. The patient was asymptomatic in the intervening period between recurrences of coronary stenoses. ECG showed rate-controlled AF with no new evidence of ischaemia and normal cardiac biomarkers. A transthoracic echocardiogram revealed an EF of 35% with an apicoanterior aneurysm and an akinetic inferoposterior wall. There was preserved contractility in other segments with a mildly dilated left ventricle (end-diastolic volume 141 ml). An angiogram revealed that the LAD was diffusely diseased with 80% stenosis in the proximal and mid segments. The distal LAD showed chronic occlusion with retrograde filling from right coronary artery (RCA) collaterals, Rentrop II. The first diagonal (D1) was a small vessel with severe ostial stenosis (80%) and diffuse disease. The LCx revealed 80% stenosis in the proximal third and the OM1 had ostial occlusion (Figure 1A). The RCA showed 100% occlusion in the mid segment (Figure 1B) with retrograde filling from the septal branches (Figure 1A). The RIMA-radial graft, in turn, was observed to have 80% ISR in the radial graft anastomosis to the OM1, albeit with TIMI 3 flow (thus becoming the only vessel with good flow in spite of ISR) (Figure 2, Moving image 1, Moving image 2). His medications included dual antiplatelet therapy, an anticoagulant, two antianginals (calcium channel blocker and ranolazine intolerance), ACEI, two lipid-lowering agents and insulin.





Figure 1. Angiogram of native left (A) and right (B) coronary arteries.



**Figure 2.** Angiogram of right internal mammary artery extended with a radial artery graft (A) and radial graft anastomosis to obtuse marginal and DES in-stent restenosis (B).

# How would I treat?

THE INVITED EXPERTS' OPINION



**Giulio G. Stefanini**<sup>2</sup>, MD, PhD; Giuseppe Ferrante<sup>2</sup>, MD, PhD; Paolo Pagnotta<sup>2</sup>, MD; Bernhard Reimers<sup>2</sup>, MD

2. Cardiovascular Department, Humanitas Research Hospital, Rozzano, Milan, Italy

The authors report an interesting case of recurrent in-stent restenosis (ISR) at an arterial graft anastomosis with an obtuse marginal branch in a patient with prior surgical and percutaneous coronary revascularisations. The case is complex for two key reasons: first, because of the clinical complexity of an elderly patient with multiple comorbidities and an aggressive coronary artery disease, who has already been treated three times with coronary artery bypass grafting, and second, because of the procedural technical challenges related to the complex access to the diseased segment.

In view of the patient's clinical history, the subocclusive ISR within the drug-eluting stent (DES) previously implanted at the site of the graft anastomosis should be considered the culprit lesion of the unstable angina episode. Therefore, we would plan a percutaneous coronary intervention (PCI) of the graft anastomosis. We would select a right brachial access - this was successful on the occasion of the previous two PCIs - a short or manually shortened 6 Fr softtip internal mammary catheter, and a guide extension catheter. Prior to attempting any balloon dilatations, we would perform intravascular ultrasound (IVUS) imaging with the aim of clarifying the mechanisms underlying ISR (i.e., to exclude a possible mechanical aetiology). In case of evidence of DES malapposition or underexpansion, we would perform a high-pressure dilatation with a noncompliant balloon, size based on the IVUS findings. In case of the absence of a mechanical ISR aetiology, we would dilate the lesion with a scoring balloon based on recent evidence of the superior

angiographic effectiveness of scoring balloon compared with standard balloon alone predilation in the setting of ISR<sup>1</sup>. After predilatation, we would proceed to the implantation of a new-generation ultrathin-strut limus-eluting stent, which has recently been shown to provide the best angiographic and clinical effectiveness in ISR lesions<sup>2</sup>. Post-dilatation of the implanted DES with a non-compliant balloon would complete the PCI procedure, followed by an IVUS control of the result.

In addition to the ISR treatment, we would also consider performing a PCI of the proximal LAD and the first diagonal branch. Based on the information provided by the authors, the arterial graft to the LAD was known to be blocked since 2002. In view of an apicoanterior aneurysm shown by the transthoracic echocardiogram, we would not consider a revascularisation of the distal LAD. Conversely, improving the perfusion of the large second septal branch and of the first diagonal branch might be of clinical benefit for this patient.

Finally, in view of the coexisting permanent atrial fibrillation, we would discharge the patient on triple antithrombotic therapy (aspirin, clopidogrel and oral anticoagulation), with the recommendation to discontinue clopidogrel after one month<sup>3</sup>.

#### **Conflict of interest statement**

G. Stefanini received speaker/consultant fees from Abbott Vascular, AstraZeneca, B. Braun, Biotronik and The Medicines Company. The other authors have no conflicts of interest to declare.

\*Corresponding author: Cardiovascular Department, Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy. E-mail: giulio.stefanini@humanitas.it

## How would I treat?

THE INVITED EXPERTS' OPINION



Fernando Alfonso<sup>3\*</sup>, MD, PhD, FESC; Paula Antuña<sup>3</sup>, MD; Fernando Rivero<sup>3</sup>, MD

3. Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain

The treatment of patients presenting with "recurrent" in-stent restenosis (ISR) is always a challenge, as the long-term clinical and angiographic results of these "frequent flyers" can never be guaranteed<sup>3,4</sup>. This conceptual concern may occasionally be aggravated by technical considerations which pose additional difficulties in obtaining satisfactory acute results. All of these issues should be addressed in the case presented by Herrera-Nogueira et al. First of all, the technical difficulties associated with this very distal lesion should be overcome in order to optimise acute results. Second, if possible, the underlying substrate accounting for the recurrent episodes of focal ISR should be unravelled<sup>4</sup>. Finally, a "best-in-class" therapeutic strategy should be selected to tackle this vexing problem definitively<sup>3,4</sup>.

Before focusing on the culprit lesion, achieving a complete revascularisation might benefit this patient with severe systolic dysfunction. However, an attempt to revascularise the occluded right coronary artery could only be justified if myocardial viability is demonstrated in the currently akinetic inferior wall. Should this be contemplated, a retrograde approach, although very challenging, might be more attractive considering the large septal branches, even if previous treatment of the proximal lesion on the left anterior descending coronary artery is needed.

Regarding the long and winding "right-mammary-radial-artery road", the authors previously solved the difficulties by selecting a brachial access, cutting the guiding catheter and using the extension of a GuideLiner V3 catheter (Vascular Solutions) to reach the lesion. The lengths of guiding catheters, balloons and stents from different companies are slightly different, and some extra long material is available. This should be checked in order to select an appropriate combination. Although using the same strategy which proved successful in the previous procedure may not appear too elegant, this remains practical and efficacious. Alternatively, we would discard the possibility of opening the occlusion of the marginal branch anterogradely, via the native circumflex coronary artery, as this patient has had surgery on this vessel on three previous occasions.

The second issue should be to unravel the potential mechanical causes triggering recurrent focal ISR<sup>4</sup>. In this regard, intracoronary

imaging remains the best strategy, although the previously discussed problems of catheter lengths must be considered. From the images provided, it appears clear that the stent was placed in the true anastomosis (i.e., crossing from the graft to the native vessel). In some patients "hinge" segments (active kinking points) may explain recurrent focal ISR. This scenario might indeed be a possibility according to the moving images provided. In extreme circumstances, this could generate a "stent fracture"<sup>4</sup>. Most investigators would select a drug-eluting stent (DES) rather than a drug-eluting balloon (DEB), should a stent fracture be identified. The same applies in cases with a focal pattern of "edge" ISR, although, again, the images suggest a focal ISR within the stent body. Incidentally, DES provide excellent results in mammary conduits<sup>5</sup>. Finally, in patients with resistant localised stent underexpansion, ultra-highpressure non-compliant balloons should be used<sup>4</sup>. Optical coherence tomography has much higher resolution than intravascular ultrasound but this technique may be hampered if the bends of this winding conduit prevent adequate distal contrast flushing. As an alternative to intracoronary imaging, modern fluoroscopic stent enhancement techniques may also disclose stent-related mechanical problems.

Finally, once underlying mechanical problems have been ruled out or tackled, what would be the intervention of choice for this patient? In patients with BMS-ISR and DES-ISR current guidelines suggest the use of DES or DEB (recommendation/evidence: I/A)<sup>3</sup>. A DEB would be very attractive in this patient with permanent atrial fibrillation requiring chronic anticoagulation. However, ensuring maintenance of the best possible late angiographic result would also be of paramount importance in this particular case. In this regard, the RIBS IV trial (in patients with DES-ISR)<sup>6</sup> and the RIBS V trial (in patients with BMS-ISR)<sup>7</sup> demonstrated the long-term angiographic superiority of everolimus DES over DEB. Accordingly, in this challenging setting, the powerful antiproliferative properties of novel-generation DES will probably swing the pendulum in this direction.

### **Conflict of interest statement**

The authors have no conflicts of interest to declare.

\*Corresponding author: Department of Cardiology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria, IIS-IP, Universidad Autónoma de Madrid, c/Diego de León 62, 28006 Madrid, Spain. E-mail: falf@hotmail.com

### How did I treat?

#### ACTUAL TREATMENT AND MANAGEMENT OF THE CASE

### "Grandmother, mother and child"

The following treatment options were considered to treat the DES-ISR: simple balloon angioplasty, drug-eluting balloon angioplasty, drug-eluting stent implantation, CTO native vessel angioplasty or repeat CABG.

After discarding a fourth CABG and a CTO native vessel attempt (due to a challenging lesion with a J-CTO score of 4 points and jailed by a previous stent) we chose PCI of the in-stent restenosis with a different DES (everolimus)<sup>8</sup>.

The treatment dilemmas at this point were the following:

- 1. Technical difficulty in gaining access to the lesion due to its length and tortuous approach.
- 2. Unavailability of appropriately sized (short) guide catheter to reach the lesion via the brachial approach.

3. Inadequate support with risk of balloon slippage during inflation. With those problems in mind we designed a triaxial "grandmother, mother and child" system with the double objective of achieving a high support and an adequate length guide catheter system.

#### Design system (Figure 3)


Grandmother: an 8 Fr Judkins right guide catheter was shortened by around 40 centimetres and connected with a 5 centimetre segment of a 7 Fr introducer. The final catheter measured ~60 centimetres.

Mother: a 6 Fr Multipurpose (MP) guide catheter was shortened by around 20 centimetres and connected with a 5 Fr introducer. The final catheter measured ~80 centimetres.

Child: a 6 Fr GuideLiner inserted into the shortened MP.

#### Procedure

Initially, the RIMA was engaged with an internal mammary diagnostic catheter over the shortened 8 Fr guide and a 0.035" GLIDEWIRE® (Terumo Medical Corp., Tokyo, Japan) was placed in the mid segment of the graft. Then, a diagnostic catheter was exchanged for a pre-assembled 6 Fr MP1 + 6 Fr GuideLiner V3 catheter (Vascular Solutions). This mother and child system was then advanced, the 6 Fr MP guide catheter was placed in the mid segment of the RIMA (**Moving image 3**), and the GuideLiner was advanced to the second bend of the graft (after the anastomosis RIMA-radial artery) (Figure 4, Moving image 4).



**Figure 3.** Triaxial delivery system. Proximal portion (A), distal portion (B) and the whole assembled triaxial grandmother-motherchild system (C). A Judkins right 8 Fr guiding catheter (line) shortened and connected with a 7 Fr introducer (arrowheads), a Multipurpose 6 Fr guiding catheter (dashed line) shortened and connected with a 5 Fr introducer (arrowheads) and GuideLiner V3 catheter (dotted line).

The lesion was crossed with a SION guidewire (ASAHI Intecc, Aichi, Japan) and predilated with  $1.5 \times 10 \text{ mm Sprinter}^{\circledast}$  Legend (Medtronic, Minneapolis, MN, USA) and  $2.5 \times 12 \text{ mm Emerge}^{TM}$ (Boston Scientific, Marlborough, MA, USA) balloons. A  $2.5 \times 12 \text{ mm}$ SYNERGY<sup>TM</sup> DES (Boston Scientific) was advanced but could not cross the final bend in the graft anastomosis to marginal branch (Moving image 5). Finally, using a HIGH-TORQUE BALANCE HEAVYWEIGHT (BHW) guidewire (Abbott Vascular, Santa Clara, CA, USA) as a buddy wire (Moving image 6), the stent was




Figure 4. Fluoroscopic images of the system advancing into the graft (A) and the final position of the system (B).

successfully implanted (Moving image 7) with a good angiographic result (Figure 5, Moving image 8). Although the whole system was partially occluding the flow, having the system pre-assembled allowed a fast PCI procedure with only mild chest discomfort during the procedure. Small injections of 2-3 ml of contrast were enough to guide the PCI with a final volume of 86 ml. There were no post-procedural complications. The patient remained free from angina and was discharged 48 hours post intervention. At two-month follow-up the patient was in NYHA functional Class II without angina.

#### Discussion

There are several discussion points including access site, selection of guide catheter with a long and safe extension and good support, and the type of device to implant in DES-ISR. We chose the




Figure 5. Final successful result after PCI.

brachial artery puncture site to shorten the distance to the vessel ostium, because in the first attempt the balloon did not reach the stenosis via the femoral route. The most important challenge was to create a long system which allowed us to advance with assurance (safety) throughout the graft and provide a high level of support to reach the stenosis. With this purpose, and based on the triaxial system often used in neuroradiology interventions9, we created the above-mentioned system with a "grandmother, mother and child". Although a DEB could have been a good option in order to avoid a new stent layer, with similar results in short-term clinical outcomes and target lesion revascularisation compared to DES10, finally we preferred a DES implantation because the last attempt at angioplasty (June 2015) with a DEB (SeQuent® Please balloon; B. Braun, Melsungen, Germany) did not cross the stenosis. Moreover, recent studies have shown superior long-term clinical and angiographic results with EES compared with DEB in patients with DES-ISR<sup>2,6</sup>.

#### Conflict of interest statement

The authors have no conflicts of interest to declare.

#### References

1. Byrne RA. Intracoronary stenting and angiographic results: optimizing treatment of drug-eluting stent in-stent restenosis 4 (ISAR-DESIRE 4). Presented at TCT 2015. October 14, 2015, San Francisco, CA, USA.

2. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Juni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet.* 2015;386:655-64.

3. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk F, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W,

Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *EuroIntervention*. 2015;10:1024-94.

4. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. *J Am Coll Cardiol.* 2014;63:2659-73.

5. Lozano I, Serrador A, Lopez-Palop R, Lasa G, Moreu J, Pinar E, de Prado AP, Alfonso F, Jimenez Navarro M, Quero MF, Pineda J, Martin Moreiras J, Garcia San Roman K, Lopez Minguez JR, Suarez Cuervo A, Gutierrez A, Hernandez F, Baz JA, Benedicto A, Rumoroso JR, Gomez-Hospital JA, Serra V, de la Torre JM, Ruiz-Quevedo V, Botas J, Fernandez JA, Sanchez-Recalde A. Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts. *Am J Cardiol.* 2015;116:1695-9.

6. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. *J Am Coll Cardiol.* 2015;66:23-33.

7. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol.* 2014;63:1378-86.

8. Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). *JACC Cardiovasc Interv.* 2012;5: 728-37.

9. Hui FK, Schuette AJ, Spiotta AM, Yim J, Obuchowski N, Rasmussen PA, Hussain MS, Cawley CM, Dion JE, Tong FC. Flexible tip guides and intermediate catheters: two center experience and a proposed taxonomy. *J Neurointerv Surg.* 2014;6: 618-23.

10. Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. *JACC Cardiovasc Interv.* 2015;8:382-94.

#### Supplementary data

**Moving image 1.** RIMA-radial graft with DES-ISR at the radial-OM anastomosis.

Moving image 2. Radial-OM anastomosis with DES-ISR.

Moving image 3. Advancing the mother and child system.

**Moving image 4.** Final position of the mother and child system.

Moving image 5. Attempt to advance stent into the DES-ISR site.

Moving image 6. Stent advanced into DES-ISR with buddy wire.

**Moving image 7.** Stent successfully implanted in the DES-ISR site.

Moving image 8. Final successful result after PCI.